Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
EMBL Ventures is a venture capital firm based in Heidelberg, Germany, dedicated to the life sciences sector. Founded in association with the European Molecular Biology Laboratory (EMBL), the firm supports the development of companies that create commercial opportunities through innovative therapeutic treatments, pharmaceuticals, enabling technologies, and advancements in diagnostics and medical devices. The firm has been operational since approximately 2001, following the establishment of EMBLEM, its technology transfer arm.
Currently, EMBL Ventures manages assets totaling approximately EUR 68 million across two funds. The firm primarily invests in early-stage life science companies throughout Europe, focusing on those that leverage significant scientific advancements. EMBL Ventures has a strong exit track record, with notable acquisitions such as ViraTherapeutics and Luxendo, showcasing its ability to identify and support high-potential startups.
EMBL Ventures operates from two office locations in Heidelberg, Germany, and has established a robust network of major European institutional and private investors as limited partners. This affiliation with EMBL provides the firm with a unique advantage in accessing proprietary research and a vast scientific network, enhancing its investment capabilities.
EMBL Ventures exclusively targets life science technologies, investing in companies that develop new therapeutic modalities, pharmaceuticals, enabling technology platforms, diagnostics, and medical devices. The firm typically invests between EUR 3 million and EUR 5 million as a lead or co-lead investor, focusing on early-stage opportunities across Europe. This investment strategy is designed to support companies that demonstrate significant scientific advancements and commercial potential.
The firm seeks to build companies that not only innovate but also have the potential to transform healthcare solutions. EMBL Ventures emphasizes the importance of a strong scientific foundation in its portfolio companies, leveraging its close relationship with EMBL to access cutting-edge research and insights. This connection allows the firm to identify promising startups that align with its investment thesis and contribute to advancements in the life sciences sector.
EMBL Ventures has a notable portfolio that includes several high-impact companies in the life sciences sector. Key portfolio companies include:
Additional portfolio companies can be explored through EMBL Ventures' portfolio page, showcasing a diverse range of innovative life science technologies that the firm supports.
To pitch to EMBL Ventures, founders should submit their proposals through the firm's website at embl-ventures.com. It is essential to include a comprehensive deck that outlines the business model, scientific basis, market opportunity, and team qualifications. The firm prefers warm introductions but will consider direct submissions.
Response times can vary, but founders should expect to hear back within a few weeks. It is advisable to follow up if no response is received after this period.
What are EMBL Ventures' investment criteria?
EMBL Ventures focuses exclusively on life sciences, targeting companies that develop new therapeutic modalities, pharmaceuticals, enabling technology platforms, diagnostics, and medical devices. The firm looks for startups that leverage significant scientific advancements and have substantial commercial potential.
How can founders apply or pitch to EMBL Ventures?
Founders interested in pitching to EMBL Ventures can submit their proposals through the firm's website at embl-ventures.com. It is advisable to include a detailed business plan, information about the scientific foundation of the technology, and the potential market impact.
What makes EMBL Ventures different from other venture capital firms?
EMBL Ventures benefits from its affiliation with the European Molecular Biology Laboratory (EMBL), providing access to a vast scientific network and proprietary research. This connection allows the firm to identify high-potential startups in the life sciences sector more effectively than many other investors.
What is the geographic scope of EMBL Ventures' investments?
The firm primarily invests in life science companies across Europe, focusing on those that demonstrate significant scientific advancements and commercial viability.
What is the typical fund size and check size for EMBL Ventures?
EMBL Ventures manages approximately EUR 68 million across two funds. The firm typically invests between EUR 3 million and EUR 5 million in each portfolio company as a lead or co-lead investor.
What kind of post-investment involvement does EMBL Ventures have?
EMBL Ventures provides strategic guidance and support to its portfolio companies, leveraging its extensive experience in company building, mergers and acquisitions, licensing agreements, and initial public offerings (IPOs). The firm aims to actively contribute to the growth and success of its investments.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.